2 results
Approved WMOCompleted
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…
Approved WMOCompleted
The primary objective of this study is to evaluate upper extremity and trunk function in persons with SMA in different stages of the disease using 3D movement analysis, muscle force measurements, surface electromyography and activity scales. The…